




ixpressgenes.com



MEDIA KIT

TABLE OF CONTENTS

OUR STORY	01
THE LASTING IMPACTS OF TRAUMA	02
TRAUMA AUTOIMMUNE INDICATOR (TAI) SCREENING	03
HOW TAI SCREENING SUPPORTS PRACTICES	04
IN THE NEWS	05
OUR LEADERS	06
BRANDING, LOGOS, & COLLATERAL	07



OUR STORY


On February 12th, 2010, Founder Dr. Joe Ng survived an on-campus shooting in the Biology department at the University of Alabama in Huntsville. During a staff meeting, his colleague pulled a handgun and shot her co-workers, killing three of them. Following the shooting, Joe noticed a spectrum of resilience among the survivors, and the research began.

Led by 20-year combat veteran, Co-Founder, and CEO John Schmitt, we're transforming the way trauma-induced diseases are detected and prevented. We've discovered critical biomarkers that enable us to identify these conditions early—long before symptoms manifest. We're not just reacting to the impacts of trauma, we're getting ahead of them.

Why this test?

We focus on the roots rather than the symptoms. At the core of our approach is the ability to analyze RNA transcriptomes, which allows us to trace the dysregulation of specific proteins that play a vital role in the immune system, giving us deeper insights into how trauma affects the body at a molecular level.

Our work matters because trauma doesn't always show up when and how you expect it. People live with invisible wounds that can't be seen through traditional methods. We're changing that. By analyzing specific immune profiles, we can provide objective clinical data to prevent the long-term effects that trauma so often leaves behind. Informed by cutting-edge research, this is about giving people the chance to heal before they even know they need to. We will empower individuals, healthcare providers, and communities to take control of trauma-related health issues in a way that's never been possible before.



THE LASTING IMPACTS OF TRAUMA

How trauma drives disease— and the power of early detection

iXpressGenes (iXG) has uncovered that prolonged stress and trauma can lead to differentiated inflammation and autoimmune responses in the body. This inflammation can result in serious trauma-induced diseases such as Post-Traumatic Stress Disorder (PTSD). Using a simple blood test, iXpressGenes can detect specific biomarkers that indicate developing trauma-related disease before symptoms ever manifest.

Some of the most common trauma-induced diseases include:



Post-Traumatic Stress Disorder



Autoimmune Diseases



Chronic Pain Syndromes



Cardiovascular Diseases

TRAUMA BY THE NUMBERS

7%

Of The General Population Has PTSD

25%

Of Children Experience Trauma Before Age 4

20%

Of Military And Veterans Have PTSD

82%

Of PTSD in the US is non-veteran

33%

Of First Responders Have PTSD

\$230B

Annual Cost Burden Of PTSD

66%

Of Women Make Up the PTSD Population

TRAUMA AUTOIMMUNE INDICATOR (TAI) SCREENING

How does it work?

iXG uses advanced RNA biomarker technology to link immune system changes with PTSD sensitivity and resilience. The TAI screening detects early immune and neuro-inflammatory responses triggered by traumatic experiences. By analyzing RNA from blood, the TAI test identifies inflammation dysregulation, providing a novel method for assessing PTSD risk. These biomarkers, selected through RNA sequencing and inflammation-related gene research, reflect the body's response to trauma through significant expression changes. Rapidly expressed RNAs serve as key indicators of acute and chronic inflammation, offering timely insights into ongoing inflammatory processes.

TAI SCREENING ADVANTAGES

TAI screening detects conditions that may lead to trauma-induced diseases including PTSD, simplifying treatment planning with severity insights and adapting to diverse patient needs for inclusive, precise care.



- ✓ Efficient process for trauma-induced inflammation detection
- ✓ Simplifies treatment planning with severity assessment
- ✓ Adaptable to diverse patient demographics

HOW TAI SCREENING SUPPORTS PRACTICES

A Detection Tool That Fits Seamlessly Into Your Practice

As a provider, clinicians can offer patients a direct, simplified path to health, avoiding unnecessary costs and complexities. iXG's TAI screening integrates seamlessly into this model by providing a data-driven tool that complements existing clinical workflows. This isn't a one-time test but an ongoing measure—a baseline with follow-up screenings that track the effectiveness of treatment and monitor disease progression over time.

WHY TAI SCREENING SHOULD BE A REGULAR PART OF CARE



Establishes a Baseline for Trauma-Related Health

The first TAI test provides a baseline that serves as a guide for treatment. With repeated annual screenings, providers can monitor patient progress, offering insights into whether therapies effectively reduce inflammation and prevent disease.



Intervenes Early with Cost-Saving Benefits

Preventive care means cost savings for both patients and providers. By identifying trauma's biological markers early, TAI screening allows you to intervene sooner, helping avoid costly treatments later.



Moves Beyond Self-Reporting

Trauma often goes unreported due to stigma or lack of awareness. The TAI test provides objective, measurable data that help providers and patients see trauma's physical impact, enabling early intervention based on clear, actionable insights.



Supports Relapse Prevention

Regular TAI screenings help detect early signs of recurring trauma-related conditions. By monitoring biomarkers over time, providers can ensure sustained progress and adjust treatments to support long-term patient recovery.

IN THE NEWS



Blood test linking chronic illness to trauma born out of UAH shooting tragedy
Watch it [here](#).



UAH mass shooting 15 years later: Professor turning his trauma into a test
Watch it [here](#).



Huntsville's biotech industry pioneers PTSD identification and treatment
Read it [here](#).



iXG Appoints John Schmitt as CEO, Announces Nationwide TAI Test Launch
Read it [here](#).

NOTABLE PODCASTS



iXG: The Link Between Stress, Inflammation and Mental Health
Listen [here](#).



iXpressGenes with John Schmitt.
Listen [here](#).



Revolutionizing Trauma Screening with RNA:
Listen [here](#).

OUR LEADERS

For Humanity, Unapologetically Disruptive

We have a powerful team that collaborates to serve humanity through the promise of bioscience and biopsychology. Our team includes researchers, combat veterans, and business professionals with expertise in structural biology, immunology, project management, and global mental health. We innovate alongside experts in their field at HudsonAlpha Institution for Biotechnology and support commercial, institutional, and academic organizations in the community.

[See the full team here.](#)



John Schmitt

Chief Executive Officer

John Schmitt is an accomplished executive leader and biotechnology innovator with a proven track record of steering complex, high-impact projects across defense, biotechnology, and advanced manufacturing sectors. As the Chief Executive Officer of iXpressGenes, he drives the commercialization of cutting-edge biochemical screening tools that advance trauma recovery through early clinical interventions.

With a strong foundation in microbiology, immunology, and biosciences, John's technical expertise spans biotechnology, aerospace systems, and advanced manufacturing technologies. A former U.S. Army aviation leader and decorated combat veteran, John has managed billion-dollar defense programs, including the CH-47F Block II Helicopter initiative, where he excelled in engineering integration, program management, and systems development. His leadership extends to founding AMIIC, a center dedicated to accelerating advanced manufacturing adoption and workforce development. John's ability to navigate multidisciplinary environments, combined with strategic operational planning, technology commercialization, and cross-functional leadership, underscores his role as a dynamic force in scientific and technological innovation.

[Connect with John.](#)



Joseph D. Ng, Ph.D.

Chief Science Officer







Dr. Joseph David Ng is a distinguished scientist and academic leader with extensive expertise in macromolecular crystallization, structural genomics, and X-ray crystallography. As the Chief Science Officer at iXpressGenes Inc. and a Professor of Biological Sciences at the University of Alabama in Huntsville, he spearheads innovative research in structural biology, biomolecular crystallization, and biotechnology.

Dr. Ng has an impressive publication record spanning high-impact journals, reflecting his technical mastery in neutron macromolecular crystallography, protein engineering, and advanced molecular biology applications. His pioneering work has contributed to significant advancements in biomolecular structural analysis, evidenced by multiple patents and global collaborations. A recipient of numerous awards, including the SERCAT Impact Award (2024) and Innovation Award in Biology & Medicine (2016), Dr. Ng continues to influence scientific progress through research, mentorship, and leadership in international scientific communities.

[Connect with Joe.](#)

BRANDING, LOGOS, & COLLATERAL

IXG COLORS



LOGOS

Click the links below to download:

- [iXG Color Icon](#)
- [iXG White Icon](#)
- [iXG Color Horizontal](#)
- [iXG White Horizontal](#)
- [iXG Color Vertical](#)
- [iXG White Vertical](#)

COLLATERAL

Click the links below to download:

- [General Info One-Pager](#)
- [TAI Test Result Explanation Flyer](#)
- [Become a Provider Booklet](#)

Learn how we help.



[ixpressgenes.com](https://www.ixpressgenes.com)



media@ixpressgenes.com



601 Genome Way,
Huntsville, AL 35806
Suite 2023